|
시장보고서
상품코드
2120230
테라노스틱스 NGS 시장 규모, 점유율, 성장 분석 : 제품 유형별, 용도별, 기술별, 최종사용자별, 워크플로우별, 지역별 - 업계 예측(2026-2033년)Theranostic NGS Market Size, Share, and Growth Analysis, By Product Type (NGS Instruments, Reagents & Consumables), By Application, By Technology, By End User, By Workflow, By Region - Industry Forecast 2026-2033 |
||||||
세계의 테라노스틱스 NGS 시장 규모는 2024년에 18억 7,000만 달러로 평가되며, 2025년 19억 7,000만 달러에서 2033년까지 30억 1,000만 달러로 확대되어, 예측 기간(2026-2033년) 동안 CAGR 5.4%로 성장할 것으로 전망됩니다.
세계 테라노스틱스 차세대 염기서열 분석(NGS) 시장은 진단용 유전체학과 표적 치료법을 결합하여 맞춤형 의료에 혁명을 일으키고 있으며, 임상의가 분자 프로파일과 정밀 의료용 약물을 적절하게 매칭할 수 있도록 하고 있습니다. 이러한 접근 방식은 치료에 활용 가능한 변이를 조기에 발견하도록 지원하여 치료 지연을 최소화하고 환자의 예후를 개선합니다. 고속 시퀀싱의 발전과 동반진단의 활용을 배경으로, NGS 패널의 암 진료 도입이 급증하고 있습니다. 이 분야의 중요한 동향 중 하나는 보험 급여 제도의 진화입니다. 이를 통해 보험사는 분자 수준에서의 계층화를 지원하는 인센티브를 얻게 되며, 병원은 필요한 기술을 도입할 수 있게 됩니다. 이러한 추세는 임상시험 참여 확대를 촉진하고, 제약사와 진단 개발 기업 간의 협력을 강화함으로써 암, 희귀질환, 감염병 분야의 혁신적인 치료법으로 가는 길을 열어주고 있습니다.
세계 테라노스틱스 NGS 시장의 성장 촉진요인
정밀 종양학 분야에서 차세대 염기서열 분석(NGS)의 적용 확대는 분자 수준에서 최적화된 치료 경로를 추구하는 임상의들에게 큰 이점이 되며, 의료 기관들이 테라노스틱스 시퀀싱을 표준 진료에 도입하도록 촉진하고 있습니다. 이러한 추세는 맞춤형 치료의 이점에 대한 이해가 깊어짐에 따라 뒷받침되고 있으며, 공동 연구를 촉진하고 필요한 인프라에 대한 투자를 장려함으로써 궁극적으로 시장 성장을 견인하고 있습니다. 임상의들의 진단에 대한 확신이 높아짐에 따라 종합적인 검사 패널에 대한 의뢰 의향이 증가하고, 보험 환급에 관한 협의도 활발해지고 있어, 이는 시장 확장을 더욱 뒷받침하고 있습니다. 전반적으로 이러한 동향들이 결합되어 견고하고 지속적으로 진화하는 세계 테라노스틱스 NGS 시장을 형성하고 있습니다.
세계 테라노스틱스 NGS 시장의 제약요인
NGS 플랫폼에 필요한 막대한 자금 투자에 더해, 시약, 소프트웨어 라이선스, 자격을 갖춘 인력에 관련된 지속적인 비용은 많은 의료 서비스 제공자에게 큰 과제가 되고 있습니다. 이러한 높은 비용으로 인해 의료 기관은 기존 진단 기법을 우선시할 수밖에 없는 경우가 많아, 테라노스틱스 NGS의 임상적 이점이 인정되고 있음에도 불구하고 표준 진료에의 통합이 저해되어 시장 성장이 정체되고 있습니다. 또한, 대규모 유전체 검사에 대한 보험 적용 범위가 불충분하기 때문에 의료 기관은 제한된 자원을 수요가 많은 서비스에 할당할 수밖에 없으며, 그 결과 첨단 시퀀싱 기술에 대한 필수적인 투자가 더욱 미뤄지면서 이 분야의 혁신 가능성이 제한되고 있습니다.
세계 테라노스틱스 NGS 시장 동향
세계 테라노스틱스 NGS 시장에서는 표준 치료 경로에 정밀 종양학 솔루션을 통합하는 뚜렷한 추세가 나타나고 있습니다. 의료 서비스 제공자들은 NGS를 활용한 테라노스틱스를 점점 더 많이 도입하여 표적 치료를 개별 분자 프로파일에 맞춤화함으로써, 치료 현장에서 환자 치료의 질을 향상시키고 있습니다. 이러한 추세는 유전체 바이오마커에 대한 신뢰도 상승, 동반진단 승인 급증, 그리고 처방 과정의 시행착오를 최소화하면서 환자의 예후를 개선하려는 종합적인 목표에 힘입어 가속화되고 있습니다. 다학제적 종양 심의위원회가 의사결정 과정에서 유전체 데이터를 우선시함에 따라, 다양한 암 유형에 걸쳐 신속하고 정확하며 실용적인 인사이트를 제공하는 종합적인 플랫폼에 대한 수요가 높아지고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 테라노스틱스 NGS 시장 규모 : 제품 유형별
세계의 테라노스틱스 NGS 시장 규모 : 용도별
세계의 테라노스틱스 NGS 시장 규모 : 기술별
세계의 테라노스틱스 NGS 시장 규모 : 최종사용자별
세계의 테라노스틱스 NGS 시장 규모 : 워크플로우별
세계의 테라노스틱스 NGS 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.09.02Global Theranostic Ngs Market size was valued at USD 1.87 Billion in 2024 and is poised to grow from USD 1.97 Billion in 2025 to USD 3.01 Billion by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).
The global theranostic next-generation sequencing (NGS) market is revolutionizing personalized medicine by combining diagnostic genomics with targeted therapies, allowing clinicians to align molecular profiles with precision drugs. This approach aids in the early detection of actionable mutations, minimizing treatment delays and enhancing patient outcomes. The integration of NGS panels into oncology practices has surged, driven by advancements in high-throughput sequencing and the utilization of companion diagnostics. A significant trend within the sector is the evolving reimbursement ecosystem, which incentivizes insurers to support molecular stratification, thus enabling hospitals to acquire necessary technologies. This trend encourages broader clinical trial participation and fosters collaboration between pharmaceutical companies and diagnostic developers, paving the way for innovative treatments in oncology, rare diseases, and infectious diseases.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Theranostic Ngs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Theranostic Ngs Market Segments Analysis
Global theranostic ngs market is segmented by product type, application, technology, end user, workflow and region. Based on product type, the market is segmented into ngs instruments, reagents & consumables, software & bioinformatics, services and others. Based on application, the market is segmented into oncology, rare disease diagnosis, infectious disease testing, reproductive health and others. Based on technology, the market is segmented into targeted sequencing, whole exome sequencing, whole genome sequencing, RNA sequencing and others. Based on end user, the market is segmented into hospitals, clinical laboratories, research institutes, pharmaceutical & biotechnology companies and others. Based on workflow, the market is segmented into sample preparation, sequencing, data analysis, clinical interpretation and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Theranostic Ngs Market
The growing application of next-generation sequencing (NGS) in precision oncology presents a significant advantage for clinicians aiming for molecularly tailored treatment pathways, driving healthcare institutions to integrate theranostic sequencing into their standard practices. This trend is bolstered by a heightened understanding of the advantages of personalized therapy, which promotes collaborative research and encourages investment in necessary infrastructure, ultimately fueling market growth. Enhanced diagnostic confidence among clinicians leads to increased willingness to order comprehensive testing panels and strengthens conversations around reimbursement, further underpinning the expansion of the market. Overall, these dynamics collectively contribute to a robust and evolving Global Theranostic NGS market.
Restraints in the Global Theranostic Ngs Market
The significant financial investments needed for NGS platforms, along with the continuous expenses associated with reagents, software licenses, and qualified personnel, pose a considerable challenge for many healthcare providers. These high costs often drive institutions to favor traditional diagnostic approaches, hindering the integration of theranostic NGS into standard practice and stalling market growth despite its acknowledged clinical advantages. Furthermore, inadequate insurance coverage for extensive genomic testing compels providers to direct limited resources toward higher-volume services, further postponing essential investments in advanced sequencing technologies and restricting the potential for innovation in this field.
Market Trends of the Global Theranostic Ngs Market
The Global Theranostic NGS market is witnessing a significant trend towards the integration of precision oncology solutions within standard treatment pathways. Healthcare providers are increasingly leveraging NGS-driven theranostics to align targeted therapies with individual molecular profiles, enhancing patient care at the point of treatment. This trend is propelled by growing confidence in genomic biomarkers, a surge in companion diagnostic approvals, and an overarching goal to enhance patient outcomes while minimizing trial-and-error approaches to prescribing. As multidisciplinary tumor boards prioritize genomic data in their decision-making, there is a rising demand for comprehensive platforms that offer swift, accurate, and actionable insights across diverse cancer types.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Theranostic NGS Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- NGS Instruments
- Reagents & Consumables
- Software & Bioinformatics
- Services
- Others
Global Theranostic NGS Market Size by Application & CAGR (2026-2033)
- Market Overview
- Oncology
- Rare Disease Diagnosis
- Infectious Disease Testing
- Reproductive Health
- Others
Global Theranostic NGS Market Size by Technology & CAGR (2026-2033)
- Market Overview
- Targeted Sequencing
- Whole Exome Sequencing
- Whole Genome Sequencing
- RNA Sequencing
- Others
Global Theranostic NGS Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Clinical Laboratories
- Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Global Theranostic NGS Market Size by Workflow & CAGR (2026-2033)
- Market Overview
- Sample Preparation
- Sequencing
- Data Analysis
- Clinical Interpretation
- Others
Global Theranostic NGS Market Size & CAGR (2026-2033)
- North America (Product Type, Application, Technology, End User, Workflow)
- US
- Canada
- Europe (Product Type, Application, Technology, End User, Workflow)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Application, Technology, End User, Workflow)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Application, Technology, End User, Workflow)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Application, Technology, End User, Workflow)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QIAGEN N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pacific Biosciences of California, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oxford Nanopore Technologies plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BGI Genomics Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GeneDx Holdings Corp.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Personalis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Foundation Medicine, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Guardant Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Natera, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- NeoGenomics Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exact Sciences Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tempus AI, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GenomOncology LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sophia Genetics SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- 10x Genomics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Standard BioTools Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
